Neuroprotective or anti-inflammatory strategies are invaluable in multiple system atrophy
(MSA) due to its rapid progression with fatal prognosis. We evaluated the efficacy of
rituximab in patients with MSA-cerebellar type (MSA-C).
Phase:
Phase 2
Details
Lead Sponsor:
First Affiliated Hospital of Fujian Medical University